Budez CR
✅ Manages inflammatory bowel disease
✅ Reduces Crohn’s disease symptoms
✅ Controls ulcerative colitis
✅ Minimizes gastrointestinal inflammation
✅ Relieves abdominal pain
Budez CR contains Budesonide.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
⚡ Quick Answer — What is Budez CR?
Budez CR is a controlled-release oral capsule from Sun Pharma containing budesonide 3 mg — a potent synthetic glucocorticoid formulated with pH- and time-dependent release that delivers the active drug directly to the terminal ileum and ascending colon. Budesonide has ~90% first-pass hepatic metabolism, so despite being a strong glucocorticoid at the tissue level, its systemic exposure is ~10% that of an equivalent anti-inflammatory dose of prednisolone — giving fewer Cushingoid features, less HPA suppression, and less bone loss. Used for mild-to-moderate active Crohn's disease involving the terminal ileum or ascending colon, microscopic colitis (collagenous and lymphocytic), and off-label for autoimmune hepatitis. Standard adult dose: 9 mg once daily in the morning for 8–10 weeks, then taper. Systemic steroid side effects still occur — particularly with long courses, dose escalation, or strong CYP3A4 inhibitor co-prescription (e.g. ketoconazole, ritonavir, clarithromycin, grapefruit juice).
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Budez CR?
Budez CR is a controlled-release (CR) oral capsule manufactured by Sun Pharma containing budesonide 3 mg. Budesonide is a second-generation glucocorticoid that is roughly 15× as potent as hydrocortisone and 5× as potent as prednisolone at the tissue level — but uniquely, around 90% of the absorbed drug is inactivated on first pass through the liver.
Budez CR is Sun Pharma’s generic equivalent of Entocort EC / Uceris — a controlled-release oral budesonide capsule designed to release the active drug in the terminal ileum and ascending colon. On this site it is the only gut-targeted corticosteroid stocked and is the preferred first-line steroid for ileocaecal Crohn's disease and microscopic colitis. The CR coating is designed to dissolve at pH > 5.5 (terminal ileum and right colon) rather than in the stomach or duodenum, so the drug is released exactly where inflammation is most commonly active in ileocaecal Crohn's disease and microscopic colitis. This tissue-targeted delivery plus near-total hepatic first-pass metabolism is what makes Budez CR the preferred corticosteroid for gastroenterologists managing ileocaecal Crohn's in 2026 — it produces similar remission rates to prednisolone in this subgroup with roughly half the systemic steroid side-effect burden.
How Does Budez CR Work?
Budez CR achieves a gut-selective anti-inflammatory effect through three mechanisms:
- Gut-targeted delivery — the CR capsule uses a pH-dependent methacrylic acid copolymer that stays intact in stomach and proximal small bowel, then dissolves at pH 5.5 or higher in the distal small bowel and proximal colon. Peak local tissue concentration is in the terminal ileum and ascending colon — the exact sites of ileocaecal Crohn's and many cases of microscopic colitis.
- High first-pass hepatic metabolism (~90%) — absorbed budesonide is rapidly metabolised by CYP3A4 in the liver to two inactive metabolites (6β-hydroxy-budesonide and 16α-hydroxy-prednisolone). Only ~10% of the absorbed dose reaches systemic circulation, giving a markedly lower systemic steroid load than an equivalent anti-inflammatory dose of prednisolone.
- Standard glucocorticoid receptor action at the tissue site — in the intestinal mucosa, budesonide binds intracellular glucocorticoid receptors, suppresses NF-κB and AP-1 transcription factors, reduces pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8), inhibits leukocyte trafficking to the mucosa, and stabilises epithelial barrier function.
Clinical onset: symptomatic improvement in 2–4 weeks; steroid-free remission rates are comparable to conventional prednisolone (CDAI-based trials, Campieri 1997, Thomsen 1998) in the ileocaecal subgroup of Crohn's disease.
Uses and Indications
- Mild-to-moderate active Crohn's disease involving the terminal ileum and/or ascending colon — first-line corticosteroid of choice for this anatomical distribution. Less effective for proximal small-bowel or extensive colonic Crohn's.
- Microscopic colitis — both collagenous colitis and lymphocytic colitis. First-line treatment; ~80% clinical remission within 6–8 weeks. Maintenance at lower dose (3–6 mg/day) often needed after induction to prevent relapse.
- Autoimmune hepatitis (off-label) — as an alternative to prednisolone in non-cirrhotic patients, where the ~90% first-pass metabolism gives most of the hepatic anti-inflammatory effect without systemic steroid side effects. Contraindicated in cirrhosis because portal-systemic shunting bypasses first-pass metabolism.
- Eosinophilic oesophagitis (off-label, orally dispersible budesonide preferred) — not the CR formulation.
- Maintenance of remission in Crohn's disease — 6 mg/day for 3–12 months is sometimes used, though evidence for long-term maintenance is modest.
Budez CR is not indicated for: severe Crohn's disease, extensive ulcerative colitis (use prednisolone or 5-ASA), Crohn's disease confined to the stomach or proximal small bowel, perianal Crohn's (needs systemic therapy), or for general anti-inflammatory use (asthma, RA, dermatology — use different steroid formulations).
Budez CR Dosage and How to Take
Budez CR is supplied at 3 mg per controlled-release capsule.
- Active Crohn's induction: 9 mg (3 capsules) once daily in the morning for 8–10 weeks.
- Taper: reduce to 6 mg daily for 2 weeks, then 3 mg daily for 2 weeks, then stop. Abrupt stop after 8+ weeks at 9 mg/day can unmask HPA suppression.
- Microscopic colitis induction: 9 mg once daily for 6–8 weeks; taper.
- Microscopic colitis maintenance: 3–6 mg once daily (often lifelong in chronic relapsers).
- Crohn's maintenance (when used): 6 mg once daily for 3–12 months; limit use beyond 12 months where possible.
- Autoimmune hepatitis (off-label): 9 mg/day for induction, taper to 3–6 mg/day; specialist supervision only; NOT for cirrhotic patients.
- Renal impairment: no dose adjustment.
- Hepatic impairment: use caution; first-pass metabolism is compromised, so systemic exposure rises significantly. Avoid in severe liver disease / cirrhosis.
How to Take Budez CR Properly
- Swallow whole with a glass of water in the morning. Do not crush, chew, or open the capsules — crushing destroys the controlled-release coating, which would release the drug in the stomach and greatly reduce the gut-selective effect while increasing systemic absorption.
- Take at least 30 minutes before breakfast. Morning dosing mimics physiological cortisol rhythm and minimises HPA suppression.
- Avoid grapefruit and grapefruit juice entirely during treatment. Grapefruit inhibits intestinal CYP3A4, which raises budesonide systemic levels ~2–3× and dramatically increases systemic steroid side effects.
- Do not stop abruptly after 8 weeks or more at 9 mg/day. Although systemic exposure is lower than with prednisolone, HPA suppression can still occur. Taper as described above.
- Carry a steroid card if on treatment for more than 8 weeks. Tell anaesthetists, emergency clinicians, and any new prescriber about current budesonide use — stress-dose steroid cover may be required during major surgery or severe illness.
- Bone protection — for courses longer than 3 months, calcium + vitamin D supplementation is prudent. The bone-loss risk is meaningfully lower than with prednisolone but not zero; consider DEXA after 12 months of continuous use.
- Monitor for systemic steroid side effects at every review — weight gain, facial puffiness, mood change, acne, raised blood glucose, blurred vision (possible cataract/glaucoma with long-term use).
- Report any new fever, productive cough, or unhealed skin lesion promptly — steroid-induced immunosuppression is real even on budesonide.
- Avoid live vaccines during 9 mg/day induction. At 3–6 mg/day maintenance, live vaccines are usually acceptable but discuss with the prescriber. Inactivated vaccines (annual flu, pneumococcal, COVID-19, Shingrix) are fine and recommended.
- Do not combine with systemic corticosteroids (e.g. oral prednisolone) except under specialist direction — systemic side effects are then additive.
Side Effects of Budez CR
Systemic steroid side effects occur but are markedly less frequent and severe than with equivalent anti-inflammatory doses of prednisolone. Head-to-head trials show roughly 50% of the systemic side-effect burden of conventional steroids.
Common:
- Headache
- Nausea
- Fatigue
- Dyspepsia
- Mild facial puffiness (“moon face”) in a minority of patients, usually less marked than on prednisolone
- Acne
- Mood change (mild elevation, occasionally insomnia)
- Mild weight gain
- Mild glucose rise (less than prednisolone)
Less common but important:
- HPA-axis suppression with prolonged 9 mg/day dosing
- Raised blood pressure (less than prednisolone)
- Increased infection susceptibility (candidiasis, URI, occasional opportunistic infection)
- Cataract, posterior subcapsular (long-term use)
- Raised intraocular pressure and glaucoma
- Bone loss (less than prednisolone but measurable)
- Muscle weakness (steroid myopathy, rare at budesonide doses)
Rare but serious — seek urgent review:
- Adrenal crisis during/after withdrawal (hypotension, severe weakness, nausea, confusion)
- Severe infection (particularly during long courses)
- Severe psychiatric reaction
- Sudden vision change
- Hip or knee pain (possible avascular necrosis, rare)
- Anaphylaxis to capsule excipients (very rare)
Warnings and Precautions
- Active untreated infection — do not start. Budesonide masks infection signs less than systemic steroids but still meaningfully.
- Latent TB or hepatitis B — screen before prolonged immunosuppressive courses. Less critical than for biologics or JAK inhibitors but still indicated for > 3-month use.
- Cirrhosis / severe hepatic impairment — use with caution or avoid. Portal-systemic shunting bypasses first-pass metabolism, dramatically raising systemic exposure.
- Diabetes — expect modest rise in blood glucose; up-titrate oral hypoglycaemics or insulin as needed (less aggressive adjustment than on prednisolone).
- Hypertension, heart failure — monitor BP; less fluid-retention effect than prednisolone but not negligible.
- Pregnancy and breastfeeding — budesonide is considered among the preferred corticosteroids in pregnancy for IBD because of its low systemic bioavailability. Continuation or starting in pregnancy is often appropriate for active disease; specialist judgement. Compatible with breastfeeding (minimal transfer into milk).
- Osteoporosis risk — lower than with prednisolone. For long courses (> 3 months), calcium + vitamin D is prudent; DEXA after 12 months.
- Children — budesonide CR is used in paediatric IBD with appropriate dose adjustment; monitor growth.
- Anaesthesia / major surgery / severe illness — stress-dose hydrocortisone cover may be needed if on prolonged treatment. Tell anaesthetists and emergency clinicians about budesonide.
- Live vaccines — avoid at 9 mg/day induction doses; usually acceptable at 3–6 mg/day maintenance, but discuss with the prescriber. Inactivated vaccines are fine.
- Grapefruit, strong CYP3A4 inhibitors — dramatically raise systemic budesonide levels. Avoid combination if possible; if unavoidable, halve the dose and monitor.
Contraindications — Who Should NOT Take Budez CR
- Known hypersensitivity to budesonide or any capsule excipient
- Active systemic fungal infection (without antifungal cover)
- Untreated active TB, hepatitis B, or other serious infection
- Cirrhosis (for the autoimmune hepatitis indication; reconsider for IBD indications if cirrhosis is advanced)
- Severe uncontrolled diabetes, hypertension, heart failure, or psychiatric disease (relative)
- Recent live-vaccine administration at immunosuppressive doses
Drug Interactions
| Combine with | Effect | What to do |
|---|---|---|
| Grapefruit juice and strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat, nefazodone) | Dramatically reduce first-pass metabolism — systemic budesonide rises 2–8×, producing prednisolone-like systemic steroid side effects | Avoid combination. If unavoidable, halve the dose and monitor closely for Cushingoid features, HPA suppression, raised BP/glucose. |
| Moderate CYP3A4 inhibitors (erythromycin, diltiazem, fluconazole) | Raise systemic budesonide modestly | Monitor for systemic steroid side effects; consider dose reduction if combining long-term. |
| Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St John's wort) | Lower systemic budesonide — possible loss of disease control | May need a higher dose or alternative corticosteroid; specialist review. |
| Cholestyramine and other bile-acid sequestrants | May reduce budesonide absorption from the gut lumen | Separate doses by 4–6 hours. |
| NSAIDs (ibuprofen, diclofenac, naproxen) | Additive GI ulceration and bleed risk; NSAIDs can also worsen IBD activity | Avoid where possible; co-prescribe a PPI if unavoidable. |
| Systemic corticosteroids (prednisolone, methylprednisolone, dexamethasone) | Additive systemic steroid exposure | Avoid routine combination; specialist decision. |
| Other immunosuppressants (azathioprine, methotrexate, biologics, JAK inhibitors) | Additive immunosuppression (intended combination in IBD) | Common and often required; monitor for infection and steroid side effects. |
| Live vaccines (MMR, varicella, yellow fever, BCG, Zostavax, live nasal flu) | Theoretical risk of disseminated vaccine-strain infection at induction doses | Avoid during 9 mg/day induction; consider acceptable at 3–6 mg/day maintenance under specialist guidance. |
| Diabetes medications | Modest glucose rise — less than with prednisolone | Monitor blood glucose; minor dose adjustment may be needed. |
Storage Instructions
- Store at room temperature, below 25°C, in the original blister pack, protected from light and moisture.
- Do not store in the bathroom — humidity can compromise the controlled-release coating.
- Keep out of reach of children.
- Do not use after the expiry date on the pack.
- Return unused capsules to a pharmacy for disposal.
Related Alternatives on MedsBase
Other medications used in anti-inflammatory and autoimmune care stocked alongside this product:
- Barinat (baricitinib 2 / 4 mg) — JAK1/2 inhibitor for RA
- Tofe (tofacitinib 5 mg) — JAK1/3 inhibitor for RA, UC, PsA
- Azoran (azathioprine 50 mg) — classic immunosuppressant DMARD
- Lefuheal (leflunomide) — oral DMARD for rheumatoid arthritis
- Conimune ME (cyclosporine) — calcineurin inhibitor
- Wysolone (prednisolone 5 / 10 / 20 mg) — oral corticosteroid
- Medrol (methylprednisolone 4 / 8 / 16 mg) — oral corticosteroid
- Predniheal (prednisolone) — oral corticosteroid
- Hisone (hydrocortisone) — physiologic replacement steroid
- Kenacort (triamcinolone) — systemic corticosteroid
Explore the full Anti-Inflammatory & Autoimmune Care category.
Frequently Asked Questions
How is Budez CR different from prednisolone or methylprednisolone?
Three critical differences. (1) Location: the controlled-release coating delivers the drug to the terminal ileum and right colon, so it treats inflammation exactly where ileocaecal Crohn's and microscopic colitis live. (2) Systemic exposure: ~90% of absorbed budesonide is inactivated on first pass through the liver, so systemic steroid side effects are about half as common and half as severe as with an equivalent anti-inflammatory dose of prednisolone. (3) Indication: budesonide CR is specific to gut disease — it is not used for asthma, RA, lupus, or general anti-inflammatory purposes. For those, use Wysolone (prednisolone) or Medrol (methylprednisolone).
Why is grapefruit juice such a problem with Budez CR?
Grapefruit juice irreversibly inhibits intestinal CYP3A4 — the enzyme that inactivates absorbed budesonide before it reaches systemic circulation. With grapefruit in the diet, systemic budesonide levels can rise 2–8×, producing prednisolone-like Cushingoid side effects (moon face, weight gain, mood change, raised blood glucose, HPA suppression). Avoid grapefruit and grapefruit juice entirely during treatment. The same problem applies to strong CYP3A4 inhibitor drugs (ketoconazole, clarithromycin, ritonavir).
When will I feel Budez CR working?
Symptomatic improvement in Crohn's disease typically starts at 2–4 weeks of the 9 mg/day induction dose, with most patients in clinical remission by 8 weeks. Microscopic colitis usually responds faster — diarrhoea often improves within 1–2 weeks. If there is no meaningful improvement by 4 weeks in microscopic colitis or 8 weeks in Crohn's, the diagnosis or treatment plan should be reviewed by the prescriber.
Can I take Budez CR long-term?
For microscopic colitis, yes — many patients require long-term maintenance at 3–6 mg/day to stay in remission, sometimes for years. For Crohn's disease, long-term use beyond 12 months is discouraged — steroid-sparing maintenance with azathioprine, methotrexate, or a biologic is preferred once remission is induced. For autoimmune hepatitis, long-term use is standard in non-cirrhotic patients. Long-term budesonide still carries modest risk of HPA suppression, bone loss, cataract, and glaucoma — monitor accordingly.
Is Budez CR safe in pregnancy and breastfeeding?
Yes — budesonide is one of the preferred corticosteroids in pregnancy for active IBD because its low systemic bioavailability minimises fetal exposure. Continuation or starting during pregnancy is appropriate for active disease requiring steroid therapy. Compatible with breastfeeding; transfer into milk is minimal. Discuss with the gastroenterologist and obstetrician during pregnancy planning.
Do I still need to carry a steroid card on Budez CR?
Yes, if treated for more than 8 weeks at 9 mg/day. HPA-axis suppression can still occur, particularly if the drug is combined with a CYP3A4 inhibitor or if grapefruit is consumed. A steroid card alerts emergency clinicians and anaesthetists to your steroid exposure and the possible need for stress-dose hydrocortisone cover during severe illness, trauma or surgery.
Can I use Budez CR for ulcerative colitis?
Budesonide CR is NOT well suited to typical distal ulcerative colitis because the CR capsule releases the drug in the terminal ileum and ascending colon — which is upstream of most UC disease activity. For UC, either budesonide MMX (a different formulation specifically designed for full colonic release) or conventional prednisolone is preferred. Microscopic colitis — which is a different disease despite the “colitis” name — is responsive to Budez CR.
Why not just use prednisolone if it is cheaper and works?
Prednisolone produces similar remission rates in mild-to-moderate Crohn's but with roughly twice the systemic steroid side-effect burden: more Cushingoid features, more mood disturbance, more HPA suppression, more bone loss, more insomnia, greater diabetes and hypertension risk. Guidelines (ECCO, ACG) list budesonide CR as the preferred corticosteroid for ileocaecal Crohn's precisely because it achieves the same gut tissue effect with fewer systemic consequences. For extensive Crohn's or severe disease, prednisolone remains first-line because its systemic effect is then needed.
What if Budez CR does not induce remission in my Crohn's?
Steroid non-response or steroid dependence is an indication to escalate therapy. Options include (a) switching to prednisolone for more systemic effect, (b) starting a steroid-sparing maintenance DMARD (azathioprine via Azoran, methotrexate), or (c) starting a biologic (anti-TNF, anti-integrin, IL-23 inhibitor) depending on disease pattern and severity. Specialist gastroenterology input is essential once budesonide fails.
Other Gastro Health Medications
- Asacol — Mesalamine 400 mg DR (UC remission)
- Mesacol — Mesalamine 400 mg DR
- Saaz — Sulfasalazine 500 mg (UC + Crohn’s)
- Pentasa Suppositories — Mesalazine 1 g (distal UC)
- Rifagut — Rifaximin 400/550 mg (gut-selective)
- Browse all Gastro Health Medications
More options in Anti Inflammatory & Autoimmune Care
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Quantity | 30 Capsule/s, 60 Capsule/s, 90 Capsule/s, 180 Capsule/s |
|---|
Budez CR
Ερωτήσεις & Απαντήσεις
Budez CR
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές